Martin C. Graham - Concepedia

Author

Martin C. Graham

Also Known As

Graham M, M C Graham, M Graham, M. C. Graham, M. Graham, M.C Graham, M.C. Graham, MARTIN C. GRAHAM, Marc Graham, Martin C. Graham

Publications

2.2K

Citations

H-Index

Concepts

All Affiliations

Memorial Sloan Kettering Cancer Center Cornell University General Electric (United States)

About

Martin C. Graham is an author at Memorial Sloan Kettering Cancer Center specializing in radiology, health sciences, and nuclear medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Health Sciences	12	12	960
2	Medicine	11	13	896
3	Engineering	6	6	214
4	Public Health	3	3	51
5	Applied Physics	1	1	13

Martin C. Graham

Publications

2.1K

Citations

H-Index

Page 1

	Year	Citations
Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts. S Welt, C R Divgi, Andrew M. Scott, Journal of Clinical Oncology	1994	258
A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. David A. Scheinberg, Dennis Lovett, Chaitanya Divgi, Journal of Clinical Oncology Mixed-phenotype Acute LeukemiaImmunologyImmunotherapyAcute Myelogenous LeukemiaMyeloid Neoplasia	1991	227
Quantitative imaging of iodine-124 with PET. Keith S. Pentlow, Martin C. Graham, Richard M. Lambrecht, PubMed	1996	174
Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Chaitanya Divgi, Neil H. Bander, Andrew M. Scott, PubMed UrologyRadiation TherapyTumor ShrinkageMedicineRadionuclide Therapy	1998	157
Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias. Michael Schwartz, Dennis Lovett, Arlene Redner, Journal of Clinical Oncology	1993	130
PET scanning of iodine-124-3F9 as an approach to tumor dosimetry during treatment planning for radioimmunotherapy in a child with neuroblastoma. Steven M. Larson, Keith S. Pentlow, Nora D. Volkow, PubMed Oncologic ImagingPet ScanningPathologyGliomaPositron Emission Tomography	1992	111
Quantitative imaging of I‐124 using positron emission tomography with applications to radioimmunodiagnosis and radioimmunotherapy Keith S. Pentlow, Martin C. Graham, Richard M. Lambrecht, Medical Physics	1991	109
A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma: effects of tumor burden and antigen expression. David A. Scheinberg, David J. Straus, Sauh-Der Yeh, Journal of Clinical Oncology ImmunologyImmunoeditingPathologyImmunotherapyEighteen Patients	1990	91
Three-dimensional dosimetry for radioimmunotherapy treatment planning. George Sgouros, Stephen Chiu, Keith S. Pentlow, PubMed Pet-mriRadioimmunotherapy Treatment PlanningAbsorbed-dose CalculationsPositron Emission TomographyRadiation Medicine	1993	88
Phase I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma. M. S. Czuczman, David J. Straus, Chaitanya Divgi, Journal of Clinical Oncology	1993	69

Page 1